Wall Street Zen upgraded HUTCHMED to strong-buy from buy on Saturday, November 14, adding to several recent positive rating changes for the Nasdaq-listed biopharmaceutical company. The stock opened at $14.90 on Friday, close to the $14.87 consensus analyst price target, according to MarketBeat.
Analyst views remain mixed
The latest upgrade follows buy recommendations from HSBC on September 8 and Daiwa Securities Group on September 3. Both firms previously rated HUTCHMED a hold. Originally reported by MarketBeat.
Goldman Sachs took a more cautious position on July 23, cutting its price target to $14.00 from $16.00 while assigning a neutral rating. Weiss Ratings moved its assessment to sell (d+) from sell (d) on October 20.
Across the six analyst assessments, HUTCHMED has one strong-buy, three buy, one hold and one sell rating. The overall consensus remains Moderate Buy, placing Friday's opening price slightly above the average target despite the latest upgrade.
Shares trade above moving averages
HUTCHMED's Friday opening price exceeded its 50-day moving average of $14.06 and its 200-day average of $13.20. The shares have traded between $9.77 and $16.33 over the past 12 months.
The company's current ratio stands at 5.64, with a quick ratio of 5.50 and debt-to-equity ratio of 0.06. These measures provide a snapshot of short-term liquidity and borrowing relative to equity.
Institutional investors have also added exposure. Crossmark Global Holdings increased its holding by 25.0% in the third quarter to 106,185 shares, valued at $1,553,000. XY Capital expanded its position by 115.2% in the second quarter to 104,130 shares worth $1,120,000.
Hedge funds and other institutions own 8.82% of HUTCHMED's stock.
Cancer treatments anchor the business
Founded in 2000 under the Hutchison China MediTech name, the company became HUTCHMED in 2021. Its work centers on developing and commercializing medicines, particularly targeted cancer therapies.
Its products include fruquintinib, sold as Elunate in China and as Fruzaqla through a partner in the United States and other markets. Surufatinib and savolitinib are marketed in China as Sulanda and Orpathys, respectively, while its investigational pipeline covers cancer and immunological diseases.
Originally reported by MarketBeat.